2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2953

Comparison of Patient Outcomes in Primary Angiitis of the Central Nervous System and Reversible Cerebral Vasoconstriction Syndrome

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2356

Comparison of Spa Therapy with or without Physical Rehabilitation for Knee Osteoarthritis: A Randomized Controlled Trial

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 16L

Comparison of Systematic Vs Individually Tailored Rituximab Regimen to Maintain ANCA-Associated–Vasculitis Remission: Results of a Prospective, Randomized–Controlled, Phase 3 Trial

ACR Late-Breaking Poster Session

9:00AM-11:00AM: Abstract Number: 2689

Comparison of the 2016 ACR/EULAR and the 2002 AECG Classification Criteria in a Cohort of Patients with Suspected Primary SjöGren’s Syndrome

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2802

Comparison of the Clinical, Serological, and Prognostic Differences Among Juvenile-, Adult-, and Late-Onset Lupus Nephritis in Korean Patients: A Case-Control Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2589

Comparison of Two Enzyme-Linked Immunosorbent Assays Used for Drug Concentration Monitoring in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2175

Comparisons of Patients Prescribed Biosimilars or BIO-Originators for Autoimmune Diseases in Germany

Epidemiology and Public Health - Poster III

9:00AM-11:00AM: Abstract Number: 2094

Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System

Antiphospholipid Syndrome - Poster II

9:00AM-11:00AM: Abstract Number: 2820

Comprehensive Aptamer-Based Screening of 1129 Proteins Reveals Novel Urinary Biomarkers of Lupus Nephritis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2195

Conceptualizing the Life Course in the Employment Experiences of Working-Aged Adults with Arthritis: A Qualitative Study

Epidemiology and Public Health - ARHP Poster

9:00AM-11:00AM: Abstract Number: 2516

Concomitant Use of Oral Vs. Subcutaneous Methotrexate at Biologic Initiation: A Comparison of Biologic Treatment Survival in a Rheumatoid Arthritis Cohort

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2750

Concordance Between Patient and Physician Global Assessment of the Disease in Patients with Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2473

Concordance Between the Patient, Nurse and Physician Assessment of Clinical Outcomes in a Cohort of Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2775

Conductive Hearing Loss Is Common in Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2448

Contraceptive Methods in Women with Rheumatoid Arthritis

Reproductive Issues in Rheumatic Disorders - Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].